Insulet Corporation (PODD) PT Raised to $303 at Morgan Stanley
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P on track for muted open as Middle East tensions weigh; AI stocks boost Nasdaq
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Oil rises on Iran war stalemate; near-term potential for further gains seen limited
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Piper Sandler Starts SoFi Technologies (SOFI) at Overweight
- Fulcrum Therapeutics to merge with Slate Medicines in all-stock deal
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
Insulet Corporation (PODD) PT Raised to $295 at Stifel
November 5, 2021 6:43 AM EDTStifel analyst Matthew Blackman raised the price target on Insulet Corporation (NASDAQ: PODD) to $295.00 (from $275.00) while maintaining a Hold rating.
The analyst commented, "PODD 3Q results were largely in-line with Consensus despite US Covid headwinds and intensifying OUS competitive pressures. WW Sales grew... More
